



Patient Name:
Patient Phone:
Date of Birth (Age):
Sex:
Referring Dr (NPI #):
Patient ID:
Specimen ID:

Account Number:
Account Name:
Collection Date/Time:
Received Date/Time:
Reported Date/Time:

Result Name	Flag	Result	Range/Units	Status	Lab
Bilirubin, Total		0.7	0.0-1.2 / mg/dL	Final	01
Alkaline Phosphatase		58	44-121 / IU/L	Final	01
LDH		153	121-224 / IU/L	Final	01
AST (SGOT)		14	0-40 / IU/L	Final	01
ALT (SGPT)		13	0-44 / IU/L	Final	01
GGT		32	0-65 / IU/L	Final	01
Iron		97	38-169 / ug/dL	Final	01
<b>Cholesterol, Total</b>	<b>Above High Normal</b>	<b>236</b>	<b>100-199 / mg/dL</b>	<b>Final</b>	<b>01</b>
Triglycerides		74	0-149 / mg/dL	Final	01
HDL Cholesterol		51	>39 / mg/dL	Final	01
<b>LDL Chol Calc (NIH)</b>	<b>Above High Normal</b>	<b>172</b>	<b>0-99 / mg/dL</b>	<b>Final</b>	<b>01</b>
T. Chol/HDL Ratio		4.6	0.0-5.0 / ratio	Final	01
T. Chol/HDL Ratio					
Men    Women					
1/2 Avg. Risk    3.4    3.3					
Avg. Risk    5.0    4.4					
2X Avg. Risk    9.6    7.1					
3X Avg. Risk    23.4    11.0					
TSH		1.040	0.450-4.500 / uIU/mL	Final	01
Thyroxine (T4)		6.4	4.5-12.0 / ug/dL	Final	01
T3 Uptake		31	24-39 / %	Final	01
Free Thyroxine Index		2.0	1.2-4.9	Final	01

Patient Name:
Patient Phone:
Date of Birth (Age):
Sex:
Referring Dr (NPI #):
Patient ID:
Specimen ID:

Account Number:
Account Name:
Collection Date/Time:
Received Date/Time:
Reported Date/Time:

Result Name	Flag	Result	Range/Units	Status	Lab
WBC		5.2	3.4-10.8 / x10E3/uL	Final	01
RBC		5.02	4.14-5.80 / x10E6/uL	Final	01
Hemoglobin		15.1	13.0-17.7 / g/dL	Final	01
Hematocrit		45.5	37.5-51.0 / %	Final	01
MCV		91	79-97 / fL	Final	01
MCH		30.1	26.6-33.0 / pg	Final	01
MCHC		33.2	31.5-35.7 / g/dL	Final	01
RDW		13.1	11.6-15.4 / %	Final	01
Platelets		236	150-450 / x10E3/uL	Final	01
Neutrophils		56	Not Estab. / %	Final	01
Lymphs		32	Not Estab. / %	Final	01
Monocytes		7	Not Estab. / %	Final	01
Eos		4	Not Estab. / %	Final	01
Basos		1	Not Estab. / %	Final	01
Neutrophils (Absolute)		2.9	1.4-7.0 / x10E3/uL	Final	01
Lymphs (Absolute)		1.7	0.7-3.1 / x10E3/uL	Final	01
Monocytes(Absolute)		0.4	0.1-0.9 / x10E3/uL	Final	01
Eos (Absolute)		0.2	0.0-0.4 / x10E3/uL	Final	01
Baso (Absolute)		0.0	0.0-0.2 / x10E3/uL	Final	01
Immature Granulocytes		0	Not Estab. / %	Final	01
Immature Grans (Abs)		0.0	0.0-0.1 / x10E3/uL	Final	01
<b>001321 Iron and TIBC</b>					
Iron Bind.Cap.(TIBC)		294	250-450 / ug/dL	Final	01
UIBC		197	111-343 / ug/dL	Final	01

# Labcorp

Patient Name:  
 Patient Phone:  
 Date of Birth (Age):  
 Sex:  
 Referring Dr (NPI #):  
 Patient ID:  
 Specimen ID:

Account Number:  
 Account Name:  
 Collection Date/Time:  
 Received Date/Time:  
 Reported Date/Time:

Result Name	Flag	Result	Range/Units	Status	Lab
-------------	------	--------	-------------	--------	-----

Iron Saturation		33	15-55 / %	Final	01
-----------------	--	----	-----------	-------	----

### 004226 Testosterone

Testosterone		570	264-916 / ng/dL	Final	01
--------------	--	-----	-----------------	-------	----

Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.

### 010322 Prostate-Specific Ag

Prostate Specific Ag		1.0	0.0-4.0 / ng/mL	Final	01
----------------------	--	-----	-----------------	-------	----

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

### 010363 IGF-1

Patient Name:
Patient Phone:
Date of Birth (Age):
Sex:
Referring Dr (NPI #):
Patient ID:
Specimen ID:

Account Number:
Account Name:
Collection Date/Time:
Received Date/Time:
Reported Date/Time:

Result Name	Flag	Result	Range/Units	Status	Lab
Insulin-Like Growth Factor I		131	95-290 / ng/mL	Final	02

### 081950 Vitamin D, 25-Hydroxy

Vitamin D, 25-Hydroxy	Below Low Normal	22.0	30.0-100.0 / ng/mL	Final	01
-----------------------	------------------	------	--------------------	-------	----

Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2).

The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2).

1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press.
2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30.

### Performing Lab

01 - Labcorp San Diego, 13112 Evening Creek Dr So Ste 200, San Diego, CA 92128-4108, (858) 668-3700, Galloway, Jenny R MD

02 - Labcorp Burlington, 1447 York Court, Burlington, NC 27215-3361, (800) 762-4344, Nagendra, Sanjai MD

For Inquiries, the physician may contact the performing lab.

END OF REPORT